Healthcare of Ontario Pension Plan Trust Fund Has $61.02 Million Stake in Stryker Corporation $SYK

Healthcare of Ontario Pension Plan Trust Fund trimmed its stake in Stryker Corporation (NYSE:SYK) by 31.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 173,606 shares of the medical technology company’s stock after selling 79,014 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Stryker were worth $61,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of SYK. Norges Bank acquired a new stake in Stryker in the 4th quarter worth $1,822,272,000. Corient Private Wealth LLC boosted its position in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Strive Asset Management LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at about $227,389,000. Finally, Credit Agricole S A acquired a new stake in shares of Stryker during the 3rd quarter valued at about $194,045,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 0.0%

Shares of NYSE SYK opened at $312.14 on Monday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a market cap of $119.66 billion, a PE ratio of 36.13, a P/E/G ratio of 1.97 and a beta of 0.78. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $316.40 and a two-hundred day moving average of $343.79.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the firm posted $2.84 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Canaccord Genuity Group decreased their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. UBS Group decreased their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Citigroup decreased their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Leerink Partners decreased their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.